Bottneuro AG

First-in-class precision neuromodulation.

Swiss Startup - Bottneuro Additional Image

Bottneuro is a neurotech spin-off from the University of Basel building precision medicine for brain health. We've developed Miamind®, the world's first fully personalized brain stimulation technology that delivers individualized electrical fields tailored to each patient's brain anatomy. No surgery, no implants, no drugs crossing the blood-brain barrier, just physics, non-invasively, at home. Already registered as a medical device in CH/EU/UK, with reimbursement secured for treatment-resistant depression in Switzerland and clinical validation advancing across additional indications. Our lead US indication is spinocerebellar ataxia type 3, a rare disease with no approved standard of care and very strong reimbursement potential.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

21.07.2025

Drei Startups verstärken ihre Verwaltungsräte (startupticker.ch)

10.06.2025

Neue Power für Startup-Geschäftsleitungen (startupticker.ch)

27.11.2024

Development milestones to propel Medtechs to next step (startupticker.ch)

11.11.2024

Strong startup delegation at Medica 2024 (startupticker.ch)

06.09.2024

Kickfund invests at full throttle (startupticker.ch)

08.08.2024

Bottneuro launches Priority Access Program after successful study (startupticker.ch)

08.01.2024

Bottneuro advances into the clinical phase (startupticker.ch)

24.11.2023

Bottneuros Hirnstimulator bereit für den Einsatz an Patienten (startupticker.ch)

15.12.2022

Bottneuro secures CHF 4 million to develop its non-invasive Alzheimer's treatment (venturekick.ch)

15.12.2022

CHF 4 million for Bottneuro (startupticker.ch)

12.12.2022

IMD Startup Competition reveals the 2022/2023 winners (startupticker.ch)

09.05.2022

C-Level managers for tech startups (startupticker.ch)

20.12.2021

CHF 150,000 to advance personalized therapies for Alzheimer’s disease (startupticker.ch)

17.12.2021

Bottneuro wins CHF 150,000 to advance diagnosis and digital therapies for Alzheimer’s disease (venturekick.ch)

Last Tweets

Tweets by TwitterDev

08.04.2026

Innosuisse funded trial for Alzheimer's disease with the UPD Bern.

01.07.2025

Transition into commercial stage: Launch of Private Sales Program

20.11.2024

Bellevue Medical Group joins Priority Access Program

29.04.2024

Bottneuro enters the EU market with the launch of a subsidiary in Germany, supporting clinical expansion, market access, and regulatory activities across the region.

02.04.2024

Completion of Phase 1 Study

27.11.2023

Swissmedic Approval

No Jobs

Videos

Collaboration with ETH

Bottneuro:Samsung

Documents

Pitch Deck Compact

Instructions for Use

Patient Brochure

Clinical Applications

Onepager

Whitepaper

TOP 100 Swiss Startup Award

The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.

TOP 100 Swiss Startups 2024

Website

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (150'000) 2021

Website